X

Trial Profile

NGR018: Randomized Phase II Study of NGR-hTNF Plus Pegylated Liposomal Doxorubicin (PLD) Versus PLD in Platinum-resistant Ovarian Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NGR-TNF (Primary) ; Doxorubicin; Doxorubicin liposomal
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Sponsors AGC Biologics

Most Recent Events

25 Sep 2018 Status changed from active, no longer recruiting to completed.
26 Jan 2017 This trial has been completed in Italy.
01 Apr 2015 Planned End Date changed from 1 Feb 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com